Newsroom

Mallinckrodt Will Respond to U.S. House Committee on Oversight and Reform Request for Information on H.P. Acthar® Gel

January 14, 2019

Mallinckrodt confirmed  today that it is one of a dozen pharmaceutical manufacturers to receive a  request for information from Representative Elijah Cummings (D-Md.), Chairman  of the U.S. House of Representatives Committee on Oversight and Reform. The  company will cooperate with the inquiry.

The inquiry relates  to H.P. Acthar® Gel (repository corticotropin injection).

Since acquiring H.P. Acthar Gel in late 2014,  Mallinckrodt has invested more than $500 million in modernizing this important  therapy for appropriate patients.  In  accordance with Mallinckrodt's pledge on drug pricing and innovation any price  adjustments to the product have been limited to the mid-single digit percentage range, and  the company has taken no price action for Acthar in 2019. Mallinckrodt provides  discounts to this list price to payers, which the prior owner generally did not  offer.

Over the last several  years, Mallinckrodt proactively embarked upon a multi-year, multi-million  dollar endeavor to update and strengthen the foundational scientific rationale  of H.P. Acthar Gel based on modern clinical science and practice, product  presentation and manufacturing processes. These investments include seven  company-sponsored clinical trials targeting 1,100 patients and nearly three  dozen health economic outcomes research studies. To learn more on Mallinckrodt's  investment in and commitment to H.P. Acthar Gel, click here.

ABOUT  MALLINCKRODT
  Mallinckrodt is a global business that  develops, manufactures, markets and distributes specialty pharmaceutical  products and therapies. Areas of focus include autoimmune and rare diseases in  specialty areas like neurology, rheumatology, nephrology, pulmonology and  ophthalmology; immunotherapy and neonatal respiratory critical care therapies;  analgesics and gastrointestinal products. To learn more about Mallinckrodt,  visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of  distribution of important company information, such as press releases, investor  presentations and other financial information. It also uses its website to  expedite public access to time-critical information regarding the company in  advance of or in lieu of distributing a press release or a filing with the U.S.  Securities and Exchange Commission (SEC) disclosing the same information.  Therefore, investors should look to the Investor Relations page of the website  for important and time-critical information. Visitors to the website can also  register to receive automatic e-mail and other notifications alerting them when  new information is made available on the Investor Relations page of the  website.

CONTACTS
 
Media
Daniel  Yunger
Kekst  CNC
212-521-4879
mallinckrodt@kekstcnc.com

Investor Relations
Daniel J. Speciale, CPA
Investor Relations and Strategy Officer
314-654-3638
daniel.speciale@mnk.com

Government Affairs
Mark Tyndall
Vice President,  Government Affairs
202-459-4141
Mark.tyndall@mnk.com

Mallinckrodt, the "M" brand mark and the Mallinckrodt  Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2019 1/19